Revvity (RVTY) to Release Earnings on Tuesday

Revvity (NYSE:RVTY) will likely be releasing its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Revvity to post earnings of $1.02 per share and revenue of $704.6850 million for the quarter. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 7:30 AM ET.

Revvity (NYSE:RVTY) last issued its earnings results on Monday, February 2nd. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. The company had revenue of $772.06 million for the quarter, compared to analysts’ expectations of $759.81 million. Revvity had a net margin of 8.45% and a return on equity of 7.92%. Revvity’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.42 EPS. On average, analysts expect Revvity to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Revvity Stock Up 0.2%

Shares of RVTY stock opened at $86.96 on Tuesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.40 and a current ratio of 1.68. The firm’s 50-day moving average is $91.16 and its 200-day moving average is $96.94. The stock has a market cap of $9.72 billion, a price-to-earnings ratio of 41.81, a PEG ratio of 1.85 and a beta of 1.13. Revvity has a 52-week low of $81.36 and a 52-week high of $118.30.

Wall Street Analysts Forecast Growth

RVTY has been the topic of a number of research analyst reports. Jefferies Financial Group upped their target price on shares of Revvity from $100.00 to $105.00 and gave the company a “hold” rating in a report on Monday, February 2nd. Wall Street Zen cut shares of Revvity from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. TD Cowen reaffirmed a “hold” rating on shares of Revvity in a report on Tuesday, February 3rd. Barclays reaffirmed an “equal weight” rating and issued a $95.00 target price (down from $118.00) on shares of Revvity in a report on Tuesday, April 14th. Finally, Wells Fargo & Company upped their target price on shares of Revvity from $107.00 to $110.00 and gave the company an “equal weight” rating in a report on Tuesday, February 3rd. Four research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Revvity has a consensus rating of “Hold” and an average target price of $110.17.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of RVTY. HighTower Advisors LLC boosted its position in shares of Revvity by 2.6% during the 4th quarter. HighTower Advisors LLC now owns 5,141 shares of the company’s stock worth $497,000 after acquiring an additional 129 shares in the last quarter. Mackenzie Financial Corp boosted its position in shares of Revvity by 1.7% during the 3rd quarter. Mackenzie Financial Corp now owns 8,955 shares of the company’s stock worth $785,000 after acquiring an additional 154 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Revvity by 25.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 900 shares of the company’s stock worth $87,000 after acquiring an additional 185 shares in the last quarter. Schroder Investment Management Group boosted its position in shares of Revvity by 5.0% during the 3rd quarter. Schroder Investment Management Group now owns 4,751 shares of the company’s stock worth $416,000 after acquiring an additional 225 shares in the last quarter. Finally, American Century Companies Inc. boosted its position in shares of Revvity by 4.3% during the 2nd quarter. American Century Companies Inc. now owns 5,529 shares of the company’s stock worth $535,000 after acquiring an additional 227 shares in the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.